Ringerfundin B. Braun

PreclinicalSmall molecule

KKratochvil Milan, MD

Ringerfundin B. Braun is one of 4 small molecule programs targeting Volume. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VolumeUnknown status

VolumePreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Volume

#DrugCompanyPhaseTrials

Estrasorb

Novo Nordisk

Preclinical

1 2

Botox Cosmetic™

AbbVie

Preclinical

1 3

Ringerfundin B. Braun

KKratochvil Milan, MD

Preclinical

1 4

Methacholine Chloride

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Volume1 trial

Comparison of the Effects of Gelatine Versus Balanced Crystalloid Solution for Volume Therapy

Unknown status·KKratochvil Milan, MD·N/A·NCT02461329·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ringerfundin B. Braun. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ringerfundin B. Braun compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ringerfundin B. Braun. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kratochvil Milan, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKratochvil Milan, MD

Ringerfundin B. Braun

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Volume1 trial

References

Drug Info

Quick Facts

Related News